Pharmacokinetic monitoring of high-dose methotrexate - Early recognition of high-risk patients

Cancer Chemotherapy and Pharmacology

Volumn 3, Issue 3, 1979, Pages 161-166

  Evans, William E ^a   Pratt, Charles B ^a   Taylor, R Huntley ^a   Barker, Larry F ^a   Crom, William R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINATE CALCIUM; METHOTREXATE;

CANCER CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG MONITORING; HIGH RISK PATIENT; PHARMACOKINETICS; THERAPY;

BONE NEOPLASMS; DRUG THERAPY, COMBINATION; HALF-LIFE; HUMANS; KINETICS; LEUCOVORIN; METHOTREXATE; OSTEOSARCOMA; RISK; TIME FACTORS;

EID: 0018582258     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00262416     Document Type: Article

References (27)

1. Techniques in cancer chemotherapy. Use of leucovorin and other rescue agents after methotrexate treatment
2. Methotrexate pharmacokinetics
3. High dose methotrexate, not a conventional treatment
4. Threshold methotrexate concentrations for in-vivo inhibition of DNA synthesis in normal and tumorous target tissues
5. Recovery from toxicity associated with high-dose methotrexate: Prognostic factors
6. Effect of pleural effusion on highdose methotrexate kinetics
7. Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion pattern
8. High-dose methotrexate therapy of solid tumors: observations relating to clinical toxicity
9. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue
10. Toxicity of high-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) in osteogenic sarcoma
11. Kinetic model for the disposition and metabolism of moderate and highdose methotrexate in man
12. Serum distributions of citrovorum factor and 5-methyltetrahydrofolate following oral and IM administrations of calcium leucovorin in normal adults
13. High-dose methotrexate with CF rescue: Predictive value of serum methotrexate concentrations and corrective measures to avert toxicity
14. Effective absorption and utilization of oral formyltetrahydrofolate in mass
15. Role of drug concentration, duration of exposure and endogenous metabolites in determining methotrexate cytotoxicity
16. The relative concentration of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion
17. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides
18. Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-leucovorin rescue for children with malignant tumors
19. Optimization of high-dose methotrexate with leucovorin rescue therapy in L1210 leukemia and sarcoma 180 murine tumor models
20. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity
21. Clinical pharmacology of high-dose methotrexate
22. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration
23. Single”-agent activity of high-dose methotrexate with citrovorum factor rescue
24. Methotrexate tissue distribution: Prediction by a mathermatical model
25. Relative toxicity of methotrexate in several tissues of mice bearing Lewis lung carcinoma
26. Relative biochemical aspects of low and high doses of methotrexate in mice